Transcriptomics Industry - Regional Synopsis
North America Market Analysis
The North America transcriptomics market is set to reach 35.6% in 2037 with a 9.6% CAGR from 2025 to 2037. Market growth is driven mainly by the expansion of applications in drug discovery, cancer diagnostics, and precision medicine. The government funding via agencies, including the CDC, NIH, and CMS, is expanding its R&D in genomics and RNA-based diagnostics. The incorporation of transcriptomics into clinical trials and personalized treatment strategies, particularly in cancer and rare disease care, is driving demand. The increasing use of multi-omics platforms, cloud-based data analytics, and AI-assisted interpretation tools is improving infrastructure preparedness.
The U.S. transcriptomics market is expanding rapidly with the support of federal investments. Based on the NIH report, nearly USD 1.9 billion was allocated to genomics and transcriptomics research in 2023. CDC.gov efforts in the Office of Genomics and Precision Public Health are funding countrywide transcriptome surveillance projects in cancer and infectious diseases. Medicaid.gov forecasts that in 2024, USD 1.6 billion would be spent on transcriptomics-related therapies, with state Medicaid programs boosting coverage for RNA sequencing diagnostics, notably in cancer.
Europe Market Insights
The transcriptomics market in Europe is the fastest-growing sector and is expected to reach 29.3% of market share with 9.2% CAGR in 2037. The market in Europe is mainly driven by the robust government funding, strategic healthcare reforms, and widespread adoption of personalized medicine. The European Health Data Space (health.ec.europa.eu) program is crucial to standardizing genomic data infrastructure and enabling secure cross-border research cooperation. With the EU funding €2.9 billion for omics-driven research, transcriptomics is becoming a cornerstone of public health policies. Regional trends include the rising use of multi-omics platforms, AI-powered bioinformatics, and transcriptome diagnostics integrated into early illness screening programs.
The transcriptomics market in Germany is actively expanding and projected to have a market share of 8.0% in 2037. In 2024, the market size of transcriptomics in Germany was €4.5 billion, with the support of institutional adoption and infrastructure readiness. In 2023, the German Medical Association (BÄK) included transcriptomics in cancer and cardiovascular recommendations, allowing for statutory health insurance reimbursements. The BMG's €302 million effort, beginning in 2022, encourages transcriptome data harmonization in public health laboratories. With advanced bioinformatics capacity and high R&D spending, Germany is poised to dominate the Europe market through 2037.
